Relmada Therapeutics Financial Overview
Relmada Therapeutics's market cap is currently $324.13M. The company's EPS TTM is $-0.3; its P/E ratio is ―; Relmada Therapeutics is scheduled to report earnings on November 13, 2025, and the estimated EPS forecast is $-0.17. See an overview of income statement, balance sheet, and cash flow financials.
